Evotec Appoints Rui Wang as Head of Global In Silico and AI
Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Evotec Receives Grants to Advance Tuberculosis Treatment
Evotec Announces New Nomination to Board of Directors
Evotec SE to Announce First Quarter 2026 Results on May 6, 2026
Evotec Announces Chief Financial Officer Transition
Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer
Evotec vows to further engage with investor MAK, who demanded change
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Evotec SE to announce first half-year results 2025 on 13 August 2025
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site